Welcome to our dedicated page for ITEM 9 LABS news (Ticker: INLB), a resource for investors and traders seeking the latest updates and insights on ITEM 9 LABS stock.
Item 9 Labs Corp. is a United States-based company specializing in the production of cannabis and cannabis-related products. They offer a wide range of products including flower, concentrates, distillates, and hardware. The company distributes medical cannabis strains, shatter, crumble, badder, thca, delta 8 thc, broad spectrum distillate, and live resin terpene sauce through licensed dispensaries in Arizona. Their headquarters are located in Phoenix, Arizona.
Item 9 Labs Corp. has retained Sharp Capital Advisors LLC to explore a potential sale of the Company. With two core operating businesses, Item 9 Labs and Unity Rd., the company has made significant strides in the cannabis industry. Item 9 Labs operates a highly efficient cultivation facility, while Unity Rd. is the first national cannabis dispensary franchisor. The Company also owns an additional asset in Pahrump, Nevada.
Item 9 Labs Corp. (OTCQX: INLB) announced its acquisition of The Herbal Cure, a dispensary in Denver, Colorado, which generated $5.4 million in revenue in 2021. This strategic second acquisition enhances the company's Unity Rd. franchise, supporting their national expansion efforts. The Herbal Cure includes a 5,000-square-foot facility and a cultivation license, allowing for on-site production and potential delivery services. Item 9 Labs plans to transition this flagship location within six months, pending regulatory approval and aims to introduce its award-winning products in Colorado.
Item 9 Labs Corp. (OTCQX: INLB) has announced a public offering under Regulation A, Tier 2, allowing both accredited and unaccredited investors to share in its growth. The company aims to raise up to $67.2 million by offering 28 million units, each including one share and a half warrant. This initiative is part of their Keep Cannabis Local campaign, promoting dispensary ownership in the booming cannabis market, projected to hit $45 billion in revenue by 2025. The company plans to support local entrepreneurs through its Unity Rd. franchise model.
Item 9 Labs Corp. (OTCQX: INLB) will present at the 34th Annual Roth Conference from March 13-15, 2022, in Dana Point, California. CEO Andrew Bowden is scheduled to speak on March 15 at 2:20 PM PT, discussing the company's award-winning cannabis products and franchise brand Unity Rd.. The conference aims to foster investor relationships, featuring over 500 companies across various sectors. Item 9 Labs is noted for its premium cannabis offerings and innovative franchise model, facilitating industry entry for new dispensary owners.
Item 9 Labs Corp. (OTCQX: INLB) concluded a successful first year for its Orion 710 Live Resin Pod and Battery System, launched in February 2021. The vape system offers full-spectrum flower experiences and has quickly gained popularity, selling over 54,000 units in Arizona. With the introduction of a half-gram pod in December 2021, demand has surged, with nearly 22,500 units sold in early 2022. The Orion 710 system secured top placements at multiple cannabis competitions, reinforcing its market position.
Unity Rd., a pioneering cannabis dispensary franchise from Item 9 Labs Corp. (OTCQX: INLB), is setting new standards in franchising. Chief Franchise Officer Mike Weinberger will present on February 27, 2022, at the International Franchise Association's annual convention, discussing the integration of franchising within the cannabis sector. Unity Rd. aims to educate on the economic potential of cannabis franchising, which is projected to be a $25 billion industry. The company has franchises in Boulder, Colorado, and Oklahoma City, with plans for expansion across the U.S.
Item 9 Labs Corp. (OTCQX: INLB) reported Q1 FY2022 financial results, revealing a 104% revenue increase to $6.2 million compared to Q1 FY2021. Gross profit soared 68% to $2.4 million, but the company faced an operating loss of $2.1 million (up from $0.4 million). A net loss of $3.3 million reflected significant interest expenses. The firm continues to invest, holding $12.8 million in escrow for expansion, with plans to increase cultivation space significantly in Arizona and a robust pipeline for further growth.
Unity Rd., the cannabis dispensary franchise of Item 9 Labs Corp. (OTCQX: INLB), is positioned for significant growth in 2022, having signed agreements for expansion into six states. The brand anticipates U.S. cannabis sales reaching $50 billion by 2026. Unity Rd. opened its first franchise in Boulder, Colorado, and has plans to convert existing dispensaries through a national acquisition program. The company aims to solidify its market presence and enhance franchise support, counting nearly 20 entrepreneurial groups in development. Unity Rd. has also been recognized by the International Franchise Association.
Item 9 Labs Corp. (OTCQX: INLB) announced a conference call scheduled for February 15, 2022, to discuss its financial results for Q1 FY2022, ending December 31, 2021. The filing of the 10K report is set for February 14, 2022. The management team, including CEO Andrew Bowden and CFO Bobby Mikkelsen, will lead the call. Item 9 Labs specializes in premium cannabis products and operates a unique dispensary franchise model under Unity Rd., supporting both new and existing dispensary owners with resources and knowledge.
Unity Rd., the cannabis dispensary franchise by Item 9 Labs Corp. (OTCQX: INLB), is set to present at YoungConference from January 30 to February 1 in Ft. Lauderdale, Fla. Vice President of Communications, Jayne Levy, will discuss franchising in the cannabis sector, emphasizing its growth and the support offered to new franchisees. Unity Rd. is pioneering cannabis franchising in the U.S., currently collaborating with nearly 20 entrepreneurial groups. The franchise aims to normalize cannabis franchising and is actively seeking qualified partners.
Item 9 Labs Corp. (OTCQX: INLB) reported a 170% revenue increase to $21.9 million for FY2021, compared to FY2020. Gross profit rose 161% to $8.6 million, with a flat gross margin of 40%. Despite an operating loss of $5.6 million and a net loss of $10.9 million, management highlighted successful expansion efforts, including a $19 million loan for new cultivation sites. The company also won several awards for product excellence and aims to expand its franchise model across the U.S.
FAQ
What is the current stock price of ITEM 9 LABS (INLB)?
What is the market cap of ITEM 9 LABS (INLB)?
What does Item 9 Labs Corp. specialize in?
Where is the headquarters of Item 9 Labs Corp. located?
What are some of the products offered by Item 9 Labs Corp.?
Who has Item 9 Labs Corp. retained to assist in a potential sale of the Company?
What are the two core operating businesses of Item 9 Labs Corp.?
How does Item 9 Labs Corp. distribute its products?
What additional asset does Item 9 Labs Corp. own?
When was Resolute Commercial Services appointed as the receiver for INLB?
What services does Sharp Capital Advisors LLC offer?